FDA
-
-
-
-
-
-
-
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
-
-
-
-
-
-
-
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
-
-
-
-
-
-
-
DELETED: Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person
-
-
-
-
-
-
-
Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome
-
-
-
-
-
-
-
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern
-
-
-
-
-
-
-
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
-
-
-
-
-
-
-
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

